Lifesaving programme to prevent post-birth bleeding wins Times Higher Education STEM Award

A cost-effective intervention for postpartum haemorrhage, which has reduced maternal deaths worldwide by 60%, has won a major award in UK Higher Education.

The E-MOTIVE programme led by BHP founder-member the University of Birmingham and the World Health Organisation (WHO), with partners around the world, has been awarded Times Higher Education’s 2025 STEM award for best research in science, technology, engineering or mathematics.

The award was given to the low-cost set of interventions, which are being used to reduce deaths from childbirth-related bleeding – the leading cause of maternal mortality worldwide. It affects an estimated 24 million women each year and results in around 70,000 deaths – mostly in low and middle-income countries – equivalent to one death every seven minutes.

Professor Adam Devall from the University of Birmingham and an author of the study said: “We are delighted that E-MOTIVE has received recognition from the Times Higher Education awards, demonstrating the high calibre of research undertaken at the University of Birmingham.

“Childbirth-related bleeding is a major risk to life for women around the world, affecting an estimated 24 million women each year. E-MOTIVE is a powerful toolkit that is already being employed globally to dramatically reduce the numbers of women dying from excessive bleeding during childbirth.

“Continued international collaboration could see EMOTIVE prevent up to 20,000 maternal deaths a year, marking a revolution in maternal care.”

Following a landmark study published in the New England Journal of Medicine, the WHO has convened a group to draft its first official guidelines on bundled PPH care. It stated that bundled treatments could be provided for less than $1 per package – making them cheap enough to scale in low-income countries.

Four countries have now incorporated E-MOTIVE into their national clinical guidelines, with WHO updating its road map for addressing PPH. The Gates Foundation, which funded the trial, has pledged to invest a further $500 million (£375 million) into the treatments and further research as a result of its success.

Professor Arri Coomarasamy, Honorary Professor at the University of Birmingham who led the E-MOTIVE trial said: “E-MOTIVE has the power to radically improve women’s chances of surviving childbirth globally, helping them get the treatment they need when they need it.

“Time is of the essence when responding to postpartum bleeding, so interventions that eliminate delays in diagnosis or treatment should be gamechangers for maternal health.”

The award-winning research programme is part of the University of Birmingham’s work to end preventable death and illness in mothers affected by postpartum haemorrhage, miscarriage and other pregnancy-related conditions around the globe.

The University is leading the way in women’s health research by championing the need to test safe and effect medicine use during pregnancy and breastfeeding, including jointly leading Europe’s largest miscarriage research centre – the Tommy’s National Centre for Miscarriage Research.

The breadth of research expertise extends to other women’s health priorities, including ovarian cancer, where research has been instrumental in changing National Institute of Clinical Excellence guidelines regarding surgical approach.